Treatment and Outcomes of Patients With Ischemic Stroke During COVID-19: An Analysis From Get With The Guidelines-Stroke.

"Disclosures C. Rutan, J.G. Walchok, J.H. Williams, and Dr Alger employed by the American Heart Association. Dr Smith reports consulting Bayer, Biogen, Javelin; Associate Editor for Stroke; royalties UpToDate. Dr Fonarow reports Consulting Abbott, Amgen, CHF Solutions, Janssen, Medtronic, Merck, Novartis. Dr de Lemos reports Income DSMB or Steering Committees for Amgen, Regeneron, Eli Lilly, Consulting Jannsen. Dr Schwamm reports consulting Medtronic, LifeImage, Genentech; DSMB for Genentech, Penumbra, Diffusion Pharma; Grant funding from Medtronic, PCORI, NINDS; study drug donation from Genentech. Dr Elkind reports study drug in kind from BMS-Pfizer Alliance for Eliquis, ancillary research funding from Roche for National Institutes of Health-funded trial of stroke prevention; royalties UpToDate for stroke and COVID-19 chapters. American Heart Association officer. Dr Decker-Palmer employed by Genentech, Inc. Dr Messé reports Research funding WL Gore, Novartis, Biogen, Mallinkrodt; Personal compensation for participating in clinical event committees for Yale Cardiovascular Research Group; Co-founder, Neuralert Technologies; royalties UpToDate. S. Zhang and Dr Alhanti employed Duke Clinical Research Institute. Dr Xian reports Research funding to Duke Clinical Research Institute from the American Heart Association and Genentech. The other authors report no conflicts."

"Sources of Funding This work was sponsored by a research contract from Genentech, Inc—A Member of the Roche Group. The coauthor employed by Genentech (MDP) contributed to the study design, interpretation of data, and writing the report. The decision to submit the study for publication was mutually agreed upon by the authors and the sponsor. The Get With The Guidelines–Stroke (GWTG-Stroke) program is provided by the American Heart Association/American Stroke Association. GWTG-Stroke is sponsored, in part, by Novartis, Boehringer Ingelheim and Eli Lilly Diabetes Alliance, Novo Nordisk, Sanofi, AstraZeneca, Bayer, and Portola Pharmaceuticals."